MedTrace Logo

Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

NCT00326976 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2007-12-04

No results posted yet for this study

Summary

The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.

Conditions

Interventions

DRUG

FX06

400 mg as intravenous injection in two divided boluses

PROCEDURE

Percutaneous coronary intervention

Sponsors & Collaborators

  • Fibrex Medical Research & Development GmbH

    lead INDUSTRY

Principal Investigators

  • Dan Atar, MD · Aker University Hospital, Oslo, Norway

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Completion
2007-11-30

Countries

  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Germany
  • Lithuania
  • Netherlands
  • Poland
  • Romania
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00326976 on ClinicalTrials.gov